Does J&J's $5.5 billion talc offer cost less than the bankruptcy plans it replaced?

On July 27, 2026, Johnson & Johnson filed a Form 8-K describing a proposed resolution of its ovarian talc litigation.¹ The agreement calls for per claim payments and a $5.5 billion commitment by the company. The first payment is no more than $3 billion in 2027, and no further payments are due before 2028.¹ The resolution is conditioned on, among other things, the express participation of at least 95% of the remaining claims. The filings do not list the other conditions.¹ The press release filed with it put the remaining 76,000 claims in its headline.² In it, Erik Haas, worldwide vice president of litigation, said he was confident the company would ultimately have prevailed with further litigation, but that "this resolution allows the Company to put this matter behind it and remain focused on its mission."² J&J's two earlier bankruptcy plans were valued at about $8.9 billion and about $8 billion in present value.⁸,¹⁰

In dollars, $5.5 billion is smaller than either earlier plan, however the figure is read. That does not show that ending the litigation will cost J&J less. The earlier plans were built to pay current and future claims.⁸,¹⁰ The 2026 offer pays remaining claims. It depends on a participation level J&J has not reported, and the filings reviewed say nothing about claims not yet filed.¹,³

What did J&J commit to?

The 8-K gives three money terms. It sets a $5.5 billion commitment, caps the first payment at $3 billion in 2027, and states that nothing more is due before 2028.¹ It does not say whether $5.5 billion is a present value or a nominal sum. It gives no payment schedule for 2028 or later.¹ The passage examined says payments are per claim. It does not state an amount per claim or say how one is set.¹

The release does not say where its 76,000 figure comes from. It matches the 10-Q count of approximately 76,000 plaintiffs as of June 28, 2026, which is probably the same count. It reports "approximately 76,000 plaintiffs in the United States with direct claims against the Company and its affiliates in pending lawsuits regarding injuries allegedly due to the use of body powders containing talc, primarily JOHNSON'S Baby Powder." That sentence counts plaintiffs with pending suits. It does not count people who have not sued, and its wording covers talc body powder claims without limiting them to ovarian cases. The July 27 release uses the same 76,000 figure for the remaining ovarian claims.⁶,²

Dividing $5.5 billion by 76,000 gives about $72,000 a plaintiff.¹,⁶ That is arithmetic, not a payout figure. No filing reviewed gives an amount per claim.

What were the earlier plans worth?

The bankruptcy court ruled on March 31, 2025 in In re Red River Talc LLC, Case No. 24-90505. Its opinion says the 2023 plan "provided for the establishment of a trust funded with about $8.9 billion on a net present value basis to settle and pay all current and future talc-related claims."⁸ That plan reached all current and future talc-related claims, not only ovarian ones.⁸

On September 20, 2024, J&J announced that Red River Talc LLC had filed a prepackaged Chapter 11 case. The company said: "In aggregate, the contemplated settlement represents a present value of approximately $8 billion to be paid over 25 years, totaling approximately $10 billion nominal."¹⁰ That plan covered ovarian claims, current and future.¹⁰ In the part of the opinion retrieved, the court described the Red River plan as about $9 billion and did not call that figure a present value. It gave a net present value only for the earlier Initial Plan, about $6.45 billion.⁸ The $8 billion present value is J&J's own figure. The court's $9 billion cannot be set directly against it.

The court dismissed the Red River case. The claims agent's docket overview records the dismissal at Docket No. 1425.⁹ On March 31, 2025, J&J said it would return to the tort system. It said it had "no intent to settle or pay plaintiff lawyers on such meritless claims" and would "reverse approximately $7 billion of the previous reserve."¹¹

Three limitations apply to this record. First, the opinion used here is a copy hosted by Bailey Glasser, a plaintiff-side law firm, and not the court's own docket. Only part of its text was retrieved.⁸ Second, the docket overview is an archival mirror kept by the claims agent.⁹ Third, secondary coverage cites a figure for a May 2024 plan to J&J's 2025 annual report. That report was not opened for this piece, so the figure is not used here.

Is $5.5 billion a present value?

The 8-K does not say.¹ A present value would need a payment schedule for 2028 onward and a discount rate. The filing gives neither, so the disclosed terms do not produce one.¹

The figure can still be bounded. Suppose $5.5 billion is nominal. At most $3 billion of it arrives in 2027 and the rest comes later, so its present value at any positive discount rate is below $5.5 billion.¹ Suppose instead that $5.5 billion is already a present value. It is then $2.5 billion below J&J's own figure for Red River.¹⁰ On either reading, the offer is smaller than the $8 billion and $8.9 billion figures.⁸,¹⁰

Who does it cover?

The earlier plans were designed to pay current and future claims.⁸,¹⁰ The 2026 filings speak of the remaining claims. Neither the 8-K nor the release says whether people who have not yet filed are covered. The release calls the deal a 'comprehensive resolution' that 'brings finality' but does not define who is bound.¹,² Even at the 95% threshold, up to 5% of remaining claims could stay outside the deal.¹ A full cost comparison with the earlier plans would need the cost of those holdouts and of any future claims. Neither is in the record.

What did the third quarter show?

For the quarter ended September 27, 2026, J&J reported net earnings of $210 million, against $5,152 million a year earlier (Exhibits 99.1 and 99.2 to the October 13, 2026 8-K). That is a fall of about 96%. Pre-tax earnings were $34 million. The non-GAAP reconciliation shows a pre-tax "Litigation related" adjustment of $5,519 million, against $15 million in the third quarter of 2025. That line is not labelled as talc only, and the schedule does not itemize it.⁴,⁵,⁵,⁵,⁵

The release says third-quarter earnings per share of $0.09 reflect "a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines."³ It does not give a separate talc amount.³

Before the offer, the talc reserve stood at $3.7 billion at June 28, 2026.⁶ That reserve was a present value "comprising executed settlement agreements, litigation defense and other costs." It did not include the July offer.⁶ The filings reviewed do not show how the new charge and the old reserve combine.

Has the 95% threshold been met?

The October 13, 2026 release and its cover 8-K do not say.³,⁴ The release attributes part of a one-time charge to "the proposed talc litigation resolution."³ The word "proposed" remains. A charge recorded for a proposal does not, by itself, show that 95% of remaining claims have agreed to participate.